May is #NationalCancerResearchMonth—a time to honor the power of science. From research results to real-world impact, MRD is changing what’s possible in cancer care. #NCRM25 clonoSEQ is FDA-cleared to assess MRD in CLL, MM and ALL. For further info: rb.gy/8tju9y

Managing your disease is hard enough—getting access to MRD testing shouldn’t make it any harder. Learn more: clonoseq.com/patient/multip… clonoSEQ is FDA-cleared to assess MRD in CLL, MM, and ALL. For further info: rb.gy/8tju9y

If your patient is in remission & off treatment, you’ll still keep track of their disease. clonoSEQ can detect potential relapse early, providing confidence to plan next steps. clonoSEQ is FDA-cleared to assess MRD in CLL, MM, and ALL. For further info: rb.gy/8tju9y

Your clonoSEQ #MRD reports are now available through MyChart, an online portal where you can view new and historical test results. Learn more: clonoseq.com/get-my-clonose… clonoSEQ is FDA-cleared to assess MRD in CLL, MM, and ALL. For further info: rb.gy/8tju9y

Check out HealthTree Foundation’s podcast for multiple myeloma with Dr. Fonseca (Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽). He discusses what Measurable (Minimal) Residual Disease (MRD) testing is, how it should be used & why you should be talking to your doctor about it. #MMsm Listen here: healthtree.org/myeloma/commun…

This #ClinicalTrialsDay, we’re spotlighting the value of an upfront clonoSEQ Clonality (ID) test—helping ensure patients are eligible for clinical trials from the start. #CTD2025 clonoSEQ is FDA-cleared to assess MRD in CLL, MM and ALL. For further info: rb.gy/8tju9y

Only 7 days until ASCO—see what #MRD can do for your patients. #ASCO25 clonoSEQ is FDA-cleared to assess MRD in CLL, MM and ALL. For further info: rb.gy/8tju9y

Find us at Booth 31131 to learn about the most up-to-date information on clonoSEQ, Medicare coverage & MyChart access for patient reports. #ASCO25 clonoSEQ is FDA-cleared to assess MRD in CLL, MM, and ALL. For further info: rb.gy/8tju9y

For #MRD insights that matter. Stop by our booth to see the data. #ASCO25 clonoSEQ is FDA-cleared to assess MRD in CLL, MM, and ALL. For further info: rb.gy/8tju9y

We’re proud to be featured in 13 abstracts at ASCO this year. MRD testing is helping drive research and improve patient outcomes. #ASCO25 clonoSEQ is FDA-cleared to assess MRD in CLL, MM and ALL. For further info: rb.gy/8tju9y

Today we honor survivors & the journey that continues beyond treatment. We’re proud to support long-term care plans w/ reliable #MRD monitoring. #NCSD25 clonoSEQ is FDA-cleared to assess MRD in CLL, MM, and ALL. For further info: rb.gy/8tju9y

In ADVANCE, presented at #ASCO25, clonoSEQ helped assess depth of response to Dara-KRd in newly diagnosed #MultipleMyeloma—providing insights to support treatment decisions. clonoSEQ is FDA-cleared to assess MRD in CLL, MM and ALL. For further info: rb.gy/8tju9y

Check out how MRD is helping to guide #MultipleMyeloma treatment decisions in MIDAS, presented at #ASCO25. clonoSEQ supports data-driven decisions across treatment phases. clonoSEQ is FDA-cleared to assess MRD in CLL, MM and ALL. For further info: rb.gy/8tju9y

The ADVANCE trial supports MRD negativity as an emerging + meaningful primary endpoint in MM. MRD can help define deep, lasting responses. clonoSEQ is built to track them. #ASCO25 clonoSEQ is FDA-cleared to assess MRD in CLL, MM and ALL. For further info:rb.gy/8tju9y

#ASCO25, one phrase stands out: residual disease. clonoSEQ delivers accurate, sensitive MRD testing to track residual disease across lymphoid malignancies. clonoSEQ is FDA-cleared to assess MRD in CLL, MM and ALL. For further info: rb.gy/8tju9y

Looking forward to the latest data and discussions at #EHA2025! Visit us at Booth F.01 to explore how ongoing #MRD testing w/ clonoSEQ can help inform treatment decisions. clonoSEQ is FDA-cleared to assess MRD in CLL, MM and ALL. For further info: rb.gy/8tju9y

No Residual Sequences Detected. For clinicians & patients, a clonoSEQ MRD-negative result is more than a number. It's a sign of hope & personalized care. #MM #MRD clonoSEQ is FDA-cleared to assess MRD in CLL, MM and ALL. For further info: rb.gy/8tju9y

Studies have shown a clear correlation between myeloma disease burden in bone marrow and peripheral blood (PB), supporting PB as a reliable option for MRD monitoring. clonoSEQ is FDA-cleared to assess MRD in CLL, MM and ALL. For further info: rb.gy/8tju9y

Jim & his doctor work together as “co-pilots” in his care, using regular MRD testing w/ clonoSEQ to inform treatment decisions. Listen to his full story: clonoseq.com/patient/diffus… clonoSEQ is FDA-cleared to assess MRD in CLL, MM and ALL. For further info: rb.gy/8tju9y

clonoSEQ is the NGS MRD test of choice to help monitor MRD for hematologic malignancy patients. Learn more: clonoseq.com/patient/diffus… clonoSEQ is FDA-cleared to assess MRD in CLL, MM and ALL. For further info: rb.gy/8tju9y